首页> 美国卫生研究院文献>Springer Open Choice >Fragment screening of cyclin G-associated kinase by weak affinity chromatography
【2h】

Fragment screening of cyclin G-associated kinase by weak affinity chromatography

机译:弱亲和色谱法筛选细胞周期蛋白G相关激酶的片段

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fragment-based drug discovery (FBDD) has become a new strategy for drug discovery where lead compounds are evolved from small molecules. These fragments form low affinity interactions (dissociation constant (KD) = mM − μM) with protein targets, which require fragment screening methods of sufficient sensitivity. Weak affinity chromatography (WAC) is a promising new technology for fragment screening based on selective retention of fragments by a drug target. Kinases are a major pharmaceutical target, and FBDD has been successfully applied to several of these targets. In this work, we have demonstrated the potential to use WAC in combination with mass spectrometry (MS) detection for fragment screening of a kinase target—cyclin G-associated kinase (GAK). One hundred seventy fragments were selected for WAC screening by virtual screening of a commercial fragment library against the ATP-binding site of five different proteins. GAK protein was immobilized on a capillary HPLC column, and compound binding was characterized by frontal affinity chromatography. Compounds were screened in sets of 13 or 14, in combination with MS detection for enhanced throughput. Seventy-eight fragments (46 %) with KD < 200 μM were detected, including a few highly efficient GAK binders (KD of 2 μM; ligand efficiency = 0.51). Of special interest is that chiral screening by WAC may be possible, as two stereoisomeric fragments, which both contained one chiral center, demonstrated twin peaks. This ability, in combination with the robustness, sensitivity, and simplicity of WAC makes it a new method for fragment screening of considerable potential.
机译:基于片段的药物发现(FBDD)已成为药物发现的新策略,其中先导化合物由小分子演化而来。这些片段与蛋白质靶标形成低亲和力的相互作用(解离常数(KD)=mM--μM),这需要具有足够灵敏度的片段筛选方法。弱亲和色谱法(WAC)是一种有前途的新技术,可用于基于药物靶标选择性保留片段的片段筛选。激酶是主要的药物靶标,并且FBDD已经成功地应用于其中的一些靶标。在这项工作中,我们证明了结合WAC与质谱(MS)检测用于激酶靶标(细胞周期蛋白G相关激酶(GAK))片段筛选的潜力。通过针对五个不同蛋白质的ATP结合位点虚拟筛选商业片段库,选择了一百七十个片段用于WAC筛选。将GAK蛋白固定在毛细管HPLC柱上,并通过额叶亲和色谱对化合物的结合进行表征。以13或14组筛选化合物,并结合MS检测以提高通量。检测到KD <200μM的七十八个片段(46%),包括一些高效的GAK结合物(KD为2μM;配体效率= 0.51)。特别令人感兴趣的是,通过WAC进行手性筛选是可能的,因为两个均包含一个手性中心的立体异构片段均显示出双峰。这种能力与WAC的鲁棒性,灵敏度和简便性相结合,使其成为一种具有巨大潜力的片段筛查的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号